Loading…
Burning Rock Biotech Limited is projected to decline to $8.90 by 2027, a 0% move from its current price of $8.90. BNR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $8.53 | $8.90 | $9.29 | -0.01% |
| Aug 6 | $8.38 | $8.90 | $9.45 | -0.02% |
| Aug 7 | $8.26 | $8.90 | $9.58 | -0.03% |
| Aug 8 | $8.17 | $8.90 | $9.69 | -0.04% |
| Aug 9 | $8.09 | $8.90 | $9.79 | -0.05% |
| Aug 10 | $8.01 | $8.89 | $9.87 | -0.06% |
| Aug 11 | $7.94 | $8.89 | $9.96 | -0.07% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $7.94 | $8.89 | $9.96 | -0.07% |
| Week 2 | $7.58 | $8.89 | $10.43 | -0.13% |
| Week 3 | $7.31 | $8.88 | $10.80 | -0.20% |
| Week 4 | $7.08 | $8.88 | $11.12 | -0.26% |
| Week 5 | $6.89 | $8.87 | $11.42 | -0.33% |
| Week 6 | $6.72 | $8.86 | $11.69 | -0.39% |
| Week 7 | $6.57 | $8.86 | $11.94 | -0.46% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Burning Rock Biotech Limited develops and sells cancer therapy selection tests in the People’s Republic of China and the United States. It operates in three segments: Central Laboratory Business, In-Hospital Business, and Pharma Research and Development Services. The company offers next-generation sequencing (NGS)-based tissue, liquid biopsy cancer therapy selection, and prognosis prediction tests for various cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples.
Its key products include OncoScreen Focus, a multi-gene tumor mutation co-detection test kit for non-small cell lung cancer (NSCLC) patients; OncoScreen Plus, a pan-cancer test for tissue samples; OncoCompass Plus, a corresponding test for liquid biopsy samples; OncoCompass Target, a ctDNA liquid biopsy-based test for NSCLC; and ColonCore for assessing microsatellite loci related to MSI status and detecting mutations in genes associated with gastrointestinal and related cancers. The company also provides CanCatch, a pre-operative ctDNA detection and post-operative minimal residual disease calling for relapsed patients; OncoMaster, an automatic NGS data analysis and report interpretation machine; as well as Magnis BR-customized version of its key products. In addition, it engages in the facilitation of laboratory equipment sales and sales of reagent kits.
Burning Rock Biotech Limited was founded in 2014 and is headquartered in Guangzhou, the People’s Republic of China. It has a development and commercialization agreement with Myriad Genetics, Inc. to in-license Myriad myChoice tumor testing in China; and collaborations on clinical trials and research studies with AstraZeneca, Bayer, Johnson & Johnson, CStone, BeiGene, Abbisko Therapeutics, IMPACT Therapeutics, Boehringer Ingelheim, and Merck KGaA.
Burning Rock Biotech Limited (BNR) is a healthcare company focused on cancer therapy selection tests with operations in China and the United States. It provides NGS-based tissue and liquid biopsy tests across multiple cancer types and offers a portfolio of products for tissue and liquid biopsy analysis. The company partners with Myriad Genetics on myChoice tumor testing in China and collaborates with major pharmaceutical and biotech firms.
Founded in 2014, it is headquartered in Guangzhou, China, and serves a diversified clinical laboratory and research market within its three business segments.
In the financial landscape, BNR’s current price is $9.14 and its market capitalization is $96.39M, with a market position reflected by a rank of 4048. The stock trades within a dynamic forecast path showing gradual upside through the late 2020s and into the 2030s and beyond, with varying annual returns and bullish momentum in later years. The price trajectory is accompanied by a range of technical indicators that frame a cautious-to-bullish setup over time.
A major floor 46.1% below — a decisive break under it would weaken the trend.
The nearest floor, 18.5% below — buyers have tended to step in here.
The nearest ceiling, 32.0% above — a clean break opens room to run.
A major ceiling 152.8% above — clearing it would confirm fresh momentum.
Key BNR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of BNR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.03 | Sell | $8.98 | Sell |
| MA 10 | $9.17 | Sell | $9.17 | Sell |
| MA 20 | $9.85 | Sell | $9.40 | Sell |
| MA 50 | $9.71 | Sell | $10.75 | Sell |
| MA 100 | $13.97 | Sell | $13.26 | Sell |
| MA 200 | $17.73 | Sell | $14.39 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 42.73 | Neutral |
| Stoch RSI (14) | 11.25 | Buy |
| CCI (20) | -81.22 | Neutral |
| Williams %R (14) | -93.60 | Info |
| MACD (12,26,9) | -0.05 | Sell |
| ROC (12) | -4.30 | Sell |
| Bollinger %B (20,2) | 0.24 | Neutral |
| Stochastic %K (14) | 6.40 | Buy |
| TRIX (15) | -0.28 | Sell |
| Awesome (5,34) | -0.15 | Sell |
| Ultimate (7,14,28) | 39.70 | Neutral |
| Momentum (10) | -1.07 | Sell |
| Aroon Osc (25) | 32.00 | Buy |
| Hull MA (9) | 8.84 | Buy |
| ADX (14) | 16.08 | Neutral |
| ATR (14) | 0.37 | Info |
The 30-day technical picture shows a neutral stance near-term with a range of $6.56 to $12.74. The RSI(14) stands at 40, indicating modest momentum. The 50-day simple moving average is $10.82 and the 200-day simple moving average is $17.72, suggesting current price weakness versus the longer-term trend.
Support is $7.04 and resistance is $11.75, framing a near-term trading band.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $7.04 | $8.90 | $10.49 | 0% | Neutral | |
| $6.74 | $8.90 | $12.62 | 0% | Neutral | |
| $7.11 | $9.85 | $14.75 | +11% | Neutral | |
| $8.35 | $12.03 | $18.78 | +35% | Bullish | |
| $9.04 | $13.49 | $21.80 | +52% | Bullish | |
| $7.62 | $11.74 | $19.56 | +32% | Bullish | |
| $7.62 | $12.11 | $20.71 | +36% | Bullish | |
| $7.92 | $12.96 | $22.70 | +46% | Bullish | |
| $7.49 | $12.61 | $22.59 | +42% | Bullish | |
| $9.81 | $16.97 | $31.00 | +91% | Bullish | |
| $9.69 | $19.04 | $37.81 | +114% | Bullish | |
| $14.21 | $31.57 | $70.54 | +255% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $7.04 | $8.90 | $10.62 | +0.00% |
| September 2026 | $7.46 | $8.97 | $11.18 | +0.76% |
| October 2026 | $7.26 | $8.82 | $11.19 | -1.60% |
| November 2026 | $6.68 | $8.18 | $10.51 | -7.24% |
| December 2026 | $6.53 | $8.07 | $10.49 | -1.40% |
Click any year to see its month-by-month BNR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Expect BNR to range from $7.04 to $10.49 through 2026. The $8.90 average target implies a 0% move from current prices. A consolidation phase looks the most probable path here.
The BNR price prediction for 2027 points to an average of $8.90 (low $6.74, high $12.62) — a potential decline of 0% on today's $8.90. Price action looks broadly range-bound.
In 2028, BNR is projected to trade between $7.11 and $14.75, averaging $9.85 — a potential gain of +11% from today's $8.90. That is up +11% on the projected 2027 average. A consolidation phase looks the most probable path here.
Burning Rock Biotech Limited's 2029 outlook centres on $12.03, within a $8.35 to $18.78 range. That is up +22% on the projected 2028 average. That marks a +35% change versus current levels. Momentum favours further upside here.
By 2030, BNR could reach as high as $21.80, with a base case around $13.49 and support toward $9.04 — roughly +52% from $8.90. Buyers look set to stay in control over this stretch.
Expect BNR to range from $7.62 to $19.56 through 2031. The $11.74 average target implies a +32% move from current prices. That is -13% versus the projected 2030 average. Momentum favours further upside here.
The BNR price prediction for 2032 points to an average of $12.11 (low $7.62, high $20.71) — a potential gain of +36% on today's $8.90. Buyers look set to stay in control over this stretch.
In 2033, BNR is projected to trade between $7.92 and $22.70, averaging $12.96 — a potential gain of +46% from today's $8.90. That is up +7% on the projected 2032 average. Momentum favours further upside here.
Burning Rock Biotech Limited's 2034 outlook centres on $12.61, within a $7.49 to $22.59 range. That is -3% versus the projected 2033 average. That marks a +42% change versus current levels. Buyers look set to stay in control over this stretch.
By 2035, BNR could reach as high as $31.00, with a base case around $16.97 and support toward $9.81 — roughly +91% from $8.90. Momentum favours further upside here.
Expect BNR to range from $9.69 to $37.81 through 2040. The $19.04 average target implies a +114% move from current prices. That is up +12% on the projected 2035 average. Buyers look set to stay in control over this stretch.
The BNR price prediction for 2050 points to an average of $31.57 (low $14.21, high $70.54) — a potential gain of +255% on today's $8.90. Momentum favours further upside here.
Investing $1,000 in BNR today (≈ 112.359551 BNR) could be worth
$3,547.43
+$2,547.43 (+255%) by 2050 · US Dollar
Based on the average projected BNR price of $31.57 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in BNRwould be worth at today's price.
$1,000 invested in BNR on Jul 31, 2025 (≈ 173.611104 BNR) would be worth
$1,545.14
+$545.14 (+54.5%) today · 1.55× · US Dollar
Based on a BNR entry price of $5.76 vs. today's $8.9.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $8.95 | $994.41 | -0.6% |
| 1 month ago | $8.96 | $993.3 | -0.7% |
| 3 months ago | $17.09 | $520.62 | -47.9% |
| 6 months ago | $39.53 | $225.15 | -77.5% |
| 1 year ago | $5.76 | $1,545.14 | +54.5% |
| All time (5.0y) ago | $238.8 | $37.27 | -96.3% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our BNR forecast.
Our base-case forecast reaches $18.00 around 2040.
Implied market cap at $18.00: $158.65M
The multi-year forecast paints a steady, bullish long-run path. In 2026 the average price is $9.14 with no expected ROI, reflecting a neutral tone. By 2027 the average price is $8.86 with a -3.1% ROI, still neutral in sentiment.
The forecast turns bullish from 2028 onward, with 2028 average $9.93 and 8.6% ROI, and 2029 average $12.56 with a 37.5% ROI. By 2030 the average price is $13.85 and the ROI reaches 51.5% in a bullish backdrop. From 2031 to 2034 the forecast remains bullish with year-by-year gains and ROIs between roughly 28.6% and 39.6%.
The year 2035 shows a notable jump to an average of $17.66 with a 93.3% ROI. In 2040 the average price is forecast at $18.57 with a 103.2% ROI, and by 2050 the average price is $31.11 with a 240.4% ROI. The maximums rise alongside the averages, reaching $23.56 (2030), $39.67 (2040), and $71.56 (2050).
These figures point to meaningful upside potential over the long term, but they come with inherent uncertainty and are not guarantees. The bullish tilt in the later years suggests the asset could substantially exceed today’s level if the forecast path unfolds, while earlier years show more modest moves and occasional pullbacks.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $13.85 with a 51.5% ROI and a bullish sentiment.
Forecasts turn bullish from 2029 onward, with positive ROIs such as 37.5% in 2029, 51.5% in 2030, 103.2% by 2040, and 240.4% by 2050, though some earlier years show neutral sentiment and smaller gains.
No. The 2030 maximum forecast is $23.56, with higher potential in later years (e.g., $39.67 by 2040 and $71.56 by 2050).
Current price is $9.14 and market capitalization is $96.39M.
The 30-day range is $6.56 to $12.74. RSI(14) is 40, SMA50 is $10.82, SMA200 is $17.72. Support is $7.04 and resistance is $11.75.
Burning Rock Biotech Limited Community Discussion
0Share your Burning Rock Biotech Limited price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.